Skip to main content
Article thumbnail
Location of Repository

Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy

By Claudia Mehler-Wex, Michael Kölch, Julia Kirchheiner, Gisela Antony, Jörg M Fegert and Manfred Gerlach

Abstract

Most psychotropic drugs used in the treatment of children and adolescents are applied "off label" with a direct risk of under- or overdosing and a delayed risk of long-term side effects. The selection of doses in paediatric psychiatric patients requires a consideration of pharmacokinetic parameters and the development of central nervous system, and warrants specific studies in children and adolescents. Because these are lacking for most of the psychotropic drugs applied in the Child and Adolescent and Psychiatry, therapeutic drug monitoring (TDM) is a valid tool to optimise pharmacotherapy and to enable to adjust the dosage of drugs according to the characteristics of the individual patient. Multi-centre TDM studies enable the identification of age- and development-dependent therapeutic ranges of blood concentrations and facilitate a highly qualified standardized documentation in the child and adolescent health care system. In addition, they will provide data for future research on psychopharmacological treatment in children and adolescents, as a baseline for example for clinically relevant interactions with various co-medications. Therefore, a German-Austrian-Swiss "Competence Network on Therapeutic Drug Monitoring in Child and Adolescent Psychiatry" was founded [1] introducing a comprehensive internet data base for the collection of demographic, safety and efficacy data as well as blood concentrations of psychotropic drugs in children and adolescents

Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2674035
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2000). A: Anwendung von Medikamenten außerhalb der Zulassung oder ohne Zulassung bei Kindern. Monatschr Kinderheilkd
    2. (2006). Antidepressant Use in children and Adolescents in Germany. Jorunal of Child and Adolescent Psychopharmacology
    3. (2004). Boddinton E: Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet
    4. (2008). CYP2D6 Phenotype Prediction From Genotype: Which System Is the Best? Clinical Pharmacology & Therapeutics
    5. (2005). D: Neuromelanin in human dopamine neurons: Comparison with pheripheral melanins and relevance to Parkinson's disease. Progr Neurobiol
    6. (2003). Developmental pharmacology – Drug disposition, action, and therapy in infants and children.
    7. (2004). Do child psychiatrists in Germany diagnose bipolar disorders in children and adolescents? Results from a survey. Bipolar Disord
    8. (2007). et al.: Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial.
    9. (2008). Fegert JM: Ethical issues in psychopharmacology of children and adolescents. Current Opinion Psychiatry
    10. (2004). Fegert JM: The Interface Between Publicly Funded and Industry-Funded Research in Pediatric Psychopharmacology: Opportunities for Integration and Collaboration. BIOL PSYCHIATRY
    11. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytoAdditional file 1 Additional figures.
    12. (2006). Glaeske G: Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiology and Drug Safety
    13. (2002). Gleiter C: Off-label prescribing to outpatient children.
    14. (1987). Human brain dopamine receptors in children and aging adults. Synapse
    15. (2007). Industrieunabhängige Forschung an Kindern und die 12. Novelle des Arzneimittelgesetzes. Monatsschrift Kinderheilkunde
    16. (2001). Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther
    17. (2008). L: Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring.
    18. (2005). Ortuño F: Bipolar disorder in children and adolescents: international perspective on epidemiology and phenomenology. Bipolar Disord
    19. (1999). Paus Tc, Evans AC, Rapoport JL: Brain development during childhood and adolescence: a longitudinal MRI study. Nature Neuroscience
    20. (2006). Peric FV, Youngstrom EA: The Relevance of Pharmacokinetic Studies in Designing Efficacy Trials in Juvenile Major Depression.
    21. (2003). Pharmacogenomics – drug disposition, drug targets, and side effects.
    22. (1999). Relling M: Pharmacogenomics: translating functional genomics into rational therapeutics. Science
    23. (2000). Survey of unlicensed and off label drug use in paediatric wards in European countries.
    24. (2007). The EU-regulation on medicinal products for paediatric use. Impacts on child and adolescent psychiatry and clinical research with minors. European Child and Adolescent Psychiatry
    25. (2007). Therapeutic Drug Monitoring of Quetiapine in Adolescents with Psychotic Disorders. Pharmacopsychiatry
    26. (2006). Treatment-Emergent Adverse Events from Selective Serotonin Reuptake Inhibitors by Age Group: Children versus Adolescents.
    27. (2000). Uneasy alliance – clinical investigators and the pharmaceutical industry.
    28. (2008). Valluri SC: A three-country comparison of psychotropic medication prevalence in youth.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.